Related Experiment Video
Updated: Jul 10, 2025
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
Dorota Kujawa1, Lukasz Laczmanski1, Slawomir Budrewicz2
1Laboratory of Genomics & Bioinformatics, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Abstract:
Multiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and function of the gut microbiota. In this review, current experimental and clinical evidence is presented for the characteristics of gut dysbiosis found in MS, as well as for its relevant links with the course of the disease and the dysregulated immune response and metabolic pathways involved in MS pathology. Furthermore, therapeutic implications of these investigations are discussed, with a range of pharmacological, dietary and other interventions targeted at the gut microbiome and thus intended to have beneficial effects on the course of MS.
Insights
Multiple sclerosis (MS) involves central nervous system damage and is linked to gut microbiota changes. Research explores gut dysbiosis in MS and its potential therapeutic targets for disease management.
Area of Science:
- Neuroimmunology
- Microbiome Research
Background:
- Multiple sclerosis (MS) is a chronic central nervous system disease characterized by autoimmune inflammation and neurodegeneration.
- The gut microbiota's composition and function are increasingly recognized as potential contributing factors in MS pathogenesis.
Purpose of the Study:
- To review current evidence on gut dysbiosis in MS.
- To examine the links between gut dysbiosis, disease progression, immune response, and metabolic pathways in MS.
- To discuss therapeutic strategies targeting the gut microbiome for MS management.
Main Methods:
- Literature review of experimental and clinical studies.
- Analysis of gut dysbiosis characteristics in MS patients.
- Examination of immune and metabolic alterations associated with gut dysbiosis in MS.
Main Results:
- Evidence suggests specific alterations in gut microbiota composition and function in individuals with MS.
- Gut dysbiosis is associated with disease course, immune dysregulation, and altered metabolic pathways in MS.
- Interventions targeting the gut microbiome show potential for managing MS.
Conclusions:
- Gut dysbiosis is a significant factor in multiple sclerosis.
- Modulating the gut microbiome offers promising therapeutic avenues for MS.
- Further research into microbiome-targeted therapies is warranted for MS treatment.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...